Neurocrine Biosciences, Inc. (NBIX) Financials

NBIX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 4.9 billion 1.5 billion
Dec. 31, 2025 4.6 billion 1.4 billion
Sept. 30, 2025 4.3 billion 1.3 billion
June 30, 2025 3.9 billion 1.2 billion

NBIX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 136.7 million 57.2 million
Dec. 31, 2025 390.8 million 58.6 million
Sept. 30, 2025 214.3 million 53.7 million
June 30, 2025 89.5 million 52.8 million

NBIX Net Income
Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 197.9 million
Dec. 31, 2025 153.7 million
Sept. 30, 2025 209.5 million
June 30, 2025 107.5 million

NBIX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 1.3 billion 406.2 million 406.2 million
Dec. 31, 2025 1.5 billion - 415.3 million
Sept. 30, 2025 1.1 billion 428.4 million 428.4 million
June 30, 2025 975.6 million - 439.1 million

NBIX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 103.4 million
Dec. 31, 2025 102.5 million
Sept. 30, 2025 102.5 million
June 30, 2025 101.0 million

NBIX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 9.1 million 296.2 million 318.5 million -
Dec. 31, 2025 2.4 million 258.2 million 301.8 million -
Sept. 30, 2025 13.2 million 250.0 million 291.6 million -
June 30, 2025 12.5 million 244.3 million 286.3 million -

NBIX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 814.5 million 13.8 million
Dec. 31, 2025 805.5 million 17.6 million
Sept. 30, 2025 794.9 million 14.0 million
June 30, 2025 687.5 million 11.3 million

NBIX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

NBIX

Price: $179.05

52 week price:
122.14
180.55

Earnings Per Share: 6.50 USD

P/E Ratio: 23.17

Exchange: NMS

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 490000

Ebitda: 15.0 million

Market Capitalization: 17.5 billion

Links: